MoneyCheck

Key Highlights BGB-B2033 achieves 36% confirmed objective response rate in liver cancer patients. Six-month durability rate reaches 74.1% at the recommended Phase 3 dosage level. CEA-targeting antibody-drug conjugate demonstrates 56% response in high-expression patients. PRMT5 inhibitor achieves 30.8% intracranial response rate in lung cancer brain metastases. Be...

Key Highlights Electric Semi truck transitions to commercial-scale manufacturing from pilot phase. $2.8 billion partnership with Nvidia funds Samsung substrate production capacity. Chip supply agreement targets self-driving technology and Optimus robotics platform. Third-quarter earnings decline to $787 million amid rising infrastructure expenses. TSLA shares ret...

TLDR Roche Holding AG (RHHBY) shares increased 2.60% on encouraging kidney drug trial outcomes. Phase 3 trial demonstrates sefaxersen achieved a 43.1% decrease in proteinuria among IgA nephropathy patients. Safety analysis revealed no unexpected adverse signals during the clinical evaluation period. Higher proportion of sefaxersen-treated patients experienced resolution...

Key Highlights CELC shares declined 0.49% to close at $65.25, followed by a 1.39% after-hours drop to $64.34. Median progression-free survival reached 21.5 months in patients without liver metastases receiving the triplet regimen. Overall response rate of 59% achieved in the triplet arm compared to 33% in the control cohort. Discontinuation due to adverse events ...

Key Highlights SGML shares advanced 4.68% to $7.83 following announcement of extended debt maturity terms. The lithium producer negotiated a six-month extension on its $100 million facility with Synergy Capital. Operations resumed October 5, yielding 7,090 tonnes of concentrate by October 22. Annual production capacity goal remains 330,000 tonnes by late 2027. Ou...